You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Claims for Patent: 11,504,370

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,504,370

Title:	Treatment of brain cancer
Abstract:	Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.
Inventor(s):	Patrice A. Lee, Shannon L. Winski, Kevin Koch
Assignee:	Array Biopharma Inc
Application Number:	US16/402,068
Patent Claims:	1. A method of treating brain metastases in a patient suffering from ErbB2 positive breast cancer with brain metastases, comprising administering to the patient a therapeutically effective amount of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, in combination with trastuzumab and capecitabine. 2. The method of claim 1, wherein the patient has been previously treated for breast cancer. 3. The method of claim 2, wherein the patient has been previously treated with trastuzumab for breast cancer. 4. The method of claim 1, wherein N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form. 5. The method of claim 4, wherein the oral dosage form is administered from about 100 m to about 1600 m per day. 6. The method of claim 2, wherein N4-(4-((1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethy1-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form. 7. The method of claim 6, wherein the oral dosage form is administered to the patient from about 100 mg to about 1600 mg per day. 8. A method of treating a patient suffering from breast cancer with brain metastases, comprising administering to the patient a therapeutically effective amount of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, in combination with trastuzumab and capecitabine. 9. The method of claim 8, wherein the breast cancer is ErbB2 positive. 10. The method of claim 8, wherein the patient has been previously treated for breast cancer. 11. The method of claim 10, wherein the patient has been previously treated with trastuzumab for breast cancer. 12. The method of claim 8, wherein N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form. 13. The method of claim 12, wherein the oral dosage form is administered from about 100 mg to about 1600 mg per day. 14. The method of claim 9, wherein N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered to the patient in an oral dosage form. 15. The method of claim 14, wherein the oral dosage form is a solid dispersion oral dosage form. 16. The method of claim 15, wherein the tablet is administered to the patient from about 100 mg to about 1600 mg per day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.